Diabetic Neuropathic Pain and Serotonin: What Is New in the Last 15 Years? - Archive ouverte HAL Access content directly
Journal Articles Biomedicines Year : 2023

Diabetic Neuropathic Pain and Serotonin: What Is New in the Last 15 Years?

Abstract

The neurotransmitter serotonin (5-hydroxytryptamine, 5-HT) is involved in numerous physiological functions and plays a key role in pain modulation including neuropathic pain. Diabetic neuropathy is a common complication of diabetes mellitus often accompanied by chronic neuropathic pain. Animal models of diabetes offer relevant tools for studying the pathophysiological mechanisms and pharmacological sensitivity of diabetic neuropathic pain and for identifying new therapeutic targets. In this review, we report data from preclinical work published over the last 15 years on the analgesic activity of drugs acting on the serotonergic system, such as serotonin and noradrenaline reuptake inhibitor (SNRI) antidepressants, and on the involvement of certain serotonin receptors-in particular 5-HT1A, 5-HT2A/2c and 5-HT6 receptors-in rodent models of painful diabetic neuropathy.
Fichier principal
Vignette du fichier
Mokhtar et al., 2023 Biomedicines.pdf (515.51 Ko) Télécharger le fichier
Origin : Publication funded by an institution
Licence : CC BY - Attribution

Dates and versions

hal-04323925 , version 1 (06-12-2023)

Identifiers

Cite

Nazarine Mokhtar, Stephane Doly, Christine Courteix. Diabetic Neuropathic Pain and Serotonin: What Is New in the Last 15 Years?. Biomedicines, 2023, Pathological Mechanisms in Diabetes 2.0, 11 (7), pp.1924. ⟨10.3390/biomedicines11071924⟩. ⟨hal-04323925⟩
13 View
17 Download

Altmetric

Share

Gmail Facebook X LinkedIn More